-
Platelet/Neutrophil Count Ratio (PNR) and Fibrinogen/Lymphocyte Count Ratio (FLR) Can Be Used as Predictive Indicators of Bone Metastasis in Non-Smoking Patients with Lung Cancer, but Not in Smoking Patients
10 Sep 2025 15:20 GMT
… of Lung Cancer Patients and Comparison of Lung Cancer Patients … of Lung Cancer Patients and Comparison of Lung Cancer Patients … in Patients with Lung Cancer
Discussion
Primary lung cancer is a … 2 viral oncogene homolog (KRAS) mutations) and a …
-
Lung Cancer: 5 Things to Know
09 Sep 2025 14:17 GMT
… to know about lung cancer.
1. Lung cancer encompasses diverse … -small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). … redefining lung cancer treatment.
The therapeutic landscape for lung cancer … with brain metastases. KRAS G12C inhibitors such …
-
Pan-Immune-Inflammation Value (PIV) and Prognostic Nutritional Index (PNI) are Associated with Distant Metastasis in Colorectal Cancer with KRAS Mutation but Not in Those with KRAS Wild-Type
10 Sep 2025 15:22 GMT
… , et al. Advanced lung cancer inflammation index predicts outcomes … defactinib in KRAS-mutated non-small cell lung cancer. Br … cycle induces ferroptosis in KRAS-mutant lung cancer. Nat Commun. … is required for mutant KRAS lung tumorigenesis. Cell Rep. 2016 …
-
FDA Grants Breakthrough Therapy Designation to Olomorasib in KRAS G12C NSCLC
10 Sep 2025 04:14 GMT
… –small cell lung cancer (NSCLC) harboring a KRAS G12C mutation … IASLC World Conference on Lung Cancer (WCLC).
In an … newly diagnosed metastatic KRAS G12C-mutant lung cancers. News release. … IASLC 2025 World Conference on Lung Cancer; September 6–9, 2025 …
-
Rezatapopt Shows Promise Against Multiple Solid Tumors in PYNNACLE Phase 2 Trial
12 Sep 2025 22:22 GMT
… cancer (n = 5), 22% in lung cancer (n = 18), and 21% in … TP53 Y220C mutation and are KRAS wild-type.1,3
Phase …
-
SMARCA2 Deficiency While Preserving SMARCA4 in Lung Adenocarcinoma Combined with Abnormal β-Catenin Expression
12 Sep 2025 11:55 GMT
… deficient non-small cell lung cancer (NSCLC) exhibit … well as EGFR and KRAS amplifications, and CDKN2A deletions … cell lung cancer.
The significant heterogeneity observed among lung cancer tumors … 2021 WHO classification of lung tumors: impact of advances …
-
Pan-RAS Inhibitors Poised to Redefine GI Cancer Care
11 Sep 2025 14:10 GMT
… drugs started working against the KRAS G12C mutation. This was … impact in lung cancer, where 40% of all KRAS mutations are KRAS G12C. … As we see so many KRAS mutations in colorectal, pancreas, … inhibitors, there are also KRAS G12D inhibitors under development. …
-
Recognizing and Testing for ROS1 in NSCLC
11 Sep 2025 03:48 GMT
… rearrangements in non-small cell lung cancer (NSCLC) have significantly advanced in … , ALK, MET, RET, BRAF, and KRAS mutations, among others. Many of …
-
TROP2-Targeted Antibody-Drug Conjugates Set to Transform NSCLC Treatment Market by 2040 | DelveInsight
10 Sep 2025 22:12 GMT
… alternative to chemotherapy for lung cancer.
Next-Generation Linker … Advancing TROP2 ADCs for lung cancer involves enhancing linker stability … of mutations such as KRAS, BRAF, c-Met, … Cell Lung Cancer Clinical Trial Analysis
Non-small Cell Lung Cancer …
-
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
10 Sep 2025 20:02 GMT
… adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC … pan-cancer genomic landscape of KRAS altered cancers and real-world …
About
© 1995-2025